000169169 001__ 169169
000169169 005__ 20240229133643.0
000169169 0247_ $$2doi$$a10.1111/apt.16438
000169169 0247_ $$2pmid$$apmid:34114659
000169169 0247_ $$2ISSN$$a0269-2813
000169169 0247_ $$2ISSN$$a0953-0673
000169169 0247_ $$2ISSN$$a1365-2036
000169169 0247_ $$2altmetric$$aaltmetric:107499605
000169169 037__ $$aDKFZ-2021-01298
000169169 041__ $$aEnglish
000169169 082__ $$a610
000169169 1001_ $$0P:(DE-He78)c392ec8a090dcfbe801f135a6212caf9$$aChen, Xuechen$$b0$$eFirst author$$udkfz
000169169 245__ $$aNon-steroidal anti-inflammatory drugs, polygenic risk score and colorectal cancer risk.
000169169 260__ $$aOxford$$bBlackwell Science$$c2021
000169169 3367_ $$2DRIVER$$aarticle
000169169 3367_ $$2DataCite$$aOutput Types/Journal article
000169169 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625148373_1990
000169169 3367_ $$2BibTeX$$aARTICLE
000169169 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169169 3367_ $$00$$2EndNote$$aJournal Article
000169169 500__ $$a#EA:C070#LA:C070# / 2021 Jul;54(2):167-175
000169169 520__ $$aThe regular use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced colorectal cancer (CRC) risk.To explore whether this association varies according to background polygenic risk for CRC.Data were collected from a large population-based case-control study on CRC in Germany. A polygenic risk score (PRS) based on 140 CRC-related risk loci was used to quantify the genetic risk. The associations of regular use of NSAIDs (≥2times per week for at least 1 year) with CRC risk were estimated in the whole population and in subgroups according to PRS levels using multivariable logistic regression. The impact of NSAIDs on CRC risk was compared to PRS using the 'genetic risk equivalent' (GRE), a recently developed metric for effective risk communication.In total 5129 CRC cases and 4093 controls were included in this analysis. The regular use of NSAIDs (including aspirin) was associated with reduced CRC risk [odds ratio (OR) 0.66, 95% confidence interval (CI) 0.59, 0.74], as was regular use of aspirin only (OR 0.73, 95% CI 0.65, 0.83), without indication of interaction with the PRS (P = 0.10 and 0.22 respectively). The effect of NSAID use was equivalent to the effect of having a 32 percentiles lower PRS (GRE -32, 95% CI -41, -22).The regular use of NSAIDs is associated with greatly reduced CRC risk regardless of individual genetic profile. With an equivalent reduction of relative risk across all polygenic risk groups, absolute risk reduction would be expected to be strongest among those with the highest polygenic risk score.
000169169 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169169 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169169 7001_ $$0P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919$$aGuo, Feng$$b1$$udkfz
000169169 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b2$$udkfz
000169169 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b3$$udkfz
000169169 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000169169 773__ $$0PERI:(DE-600)2003094-0$$a10.1111/apt.16438$$gp. apt.16438$$n2$$p167-175$$tAlimentary pharmacology & therapeutics$$v54$$x0269-2813$$y2021
000169169 909CO $$ooai:inrepo02.dkfz.de:169169$$pVDB
000169169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c392ec8a090dcfbe801f135a6212caf9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169169 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169169 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169169 9141_ $$y2021
000169169 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-27$$wger
000169169 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-27$$wger
000169169 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALIMENT PHARM THER : 2019$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-27
000169169 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALIMENT PHARM THER : 2019$$d2021-01-27
000169169 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000169169 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000169169 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000169169 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x3
000169169 980__ $$ajournal
000169169 980__ $$aVDB
000169169 980__ $$aI:(DE-He78)C070-20160331
000169169 980__ $$aI:(DE-He78)C020-20160331
000169169 980__ $$aI:(DE-He78)HD01-20160331
000169169 980__ $$aI:(DE-He78)C120-20160331
000169169 980__ $$aUNRESTRICTED